Many studies have technologically researched clinical anticancer combinations, particularly the combination progress toward specific targets (e.g., programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) [9, 10], cyclin-dependent kinase 4/6 (CDK4/6) [11], or poly (ADP-ribose) polymerase (PARP) [12]), specific therapies (e.g., immuno-oncology (IO) therapies [13–15]), specific cancer types [16, 17], or even the perspectives of future directions [4, 18]. This evidence concerns the gene CDK4 and cancer.